Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.50 |
| ▸ | CTSL | P07711 | 11/20 | 0.50 |
| ▸ | CTSB | P07858 | 10/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509783 | 1.00 | CTSS (0.50) | CTSSCTSLCTSBCTSKABCB1 | |
| SCHEMBL6182057 | 0.88 | CTSL (0.47) | CTSSCTSLCTSBCTSKABCB1 | |
| SCHEMBL854095 | 0.81 | CTSL (0.53) | CTSSCTSLCTSBCTSKABCB1 | |
| SCHEMBL6185601 | 0.81 | CTSS (0.55) | CTSSCTSLCTSBCTSK | |
| SCHEMBL7557226 | 0.79 | CTSS (0.46) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL6183071 | 0.79 | ALDH1A1 (0.43) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL5528477 | 0.75 | CTSL (0.49) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL6184235 | 0.75 | CTSL (0.45) | CTSSCTSLCTSBCTSK | |
| SCHEMBL4763089 | 0.74 | CTSK (0.44) | CTSSCTSLCTSBCTSKABCB1 | |
| SCHEMBL6183149 | 0.74 | CTSS (0.44) | CTSSCTSLCTSBCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161415-B1 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | US | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSL 14/4885CTSB 11/4885 |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSL 14/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.